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Abstract 
Background 
In the UK routinely recorded data may benefit prospective studies including randomised controlled trials 
(RCTs). In an on-going study, we aim to assess the feasibility of access and agreement of routinely recorded 
clinical and non-clinical data compared to data collected during a RCT using standard prospective methods. 
This paper will summarise available UK routinely recorded data sources and discuss our experience with the 
feasibility of accessing routinely recorded data for participants of a RCT before finally proposing 
recommendations for improving the access and implementation of routinely recorded data in RCTs.  
Methods 
Setting 
The case study RCT is the Standard and New Antiepileptic Drugs II (SANAD II) Trial, a pragmatic, UK 
multicentre, phase IV RCT assessing the clinical and cost effectiveness of antiepileptic drug treatments for 
newly diagnosed epilepsy.  
Participants 
Ninety eight participants have provided written consent to permit the request of routinely recorded data.   
Study Procedures 
Routinely recorded clinical and non-clinical data were identified and data requested through formal applications 
from available data holders for the duration participants have been recruited into SANAD II. The feasibility of 
accessing routinely recorded data during a RCT is assessed and recommendations for improving access 
proposed.  
Results 
Secondary care clinical and socio-economic data is recorded on a national basis and can be accessed, although 
there are limitations in the application process. Primary care data is recorded by a number of organisations on a 
de-identified basis and access for specific individuals has not been feasible. Access to data recorded by non-
clinical sources, including The Department for Work and Pensions and The Driving and Vehicle Licensing 
Agency, was not successful.  
Conclusions 
Recommendations discussed include further research to assess the attributes of routinely recorded data, an 
assessment of public perceptions and the development of strategies to collaboratively improve access to 
routinely recorded data for research. 
Trial Registration 
Standard and New Antiepileptic Drugs II (SANAD II (EudraCT No: 2012-001884-64, registered 05/09/2012; 
ISRCTN Number: 30294119, registered 03/07/2012))  
Key words  
Routine Data, Administrative Data, Feasibility, Data Collection
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Background 
There is a plethora of individual-level routinely recorded data in the UK. These data are recorded to 
fulfil specific, defined purposes and are regulated for security, confidentiality and disclosure by The 
Data Protection Act 1998 [1] and Freedom of Information Act 2000 [2]. Access to routinely recorded 
data for ‘secondary purposes’ such as clinical research is permitted providing there is demonstrable 
secondary benefit.  
The potential for routinely recorded data to inform clinical research and Health Technology 
Assessment (HTA) has long been recognised [3]. Presently, there are a number of sources of routinely 
recorded primary and secondary care clinical data with regional or national coverage. However, 
limitations with accuracy of coding, confidentiality, ownership and data access have been previously 
identified as significant barriers to using  routinely recorded data in research [4].  
There are numerous examples of retrospective observational, record linkage population studies where 
routine sources have proved a valid and efficient method for providing data for clinical research [5]. 
In the context of prospective research such as randomised controlled trials (RCTs) routinely recorded 
data have been used to inform judgements about the feasibility of sample size and recruitment targets 
[6] and measuring participant outcomes [3, 7].   Pragmatic cluster RCTs have been coordinated 
through routine data sources including patient recruitment, randomisation, administration of 
intervention and trial assessments, such as through the Clinical Practice Research Datalink (CPRD) 
[8]. The majority of RCTs incur costs as clinicians assess participants, record outcomes and complete 
Case Report Forms - hence using routinely recorded data may provide an efficient alternative method 
for data collection in addition to reducing the burden on participants. Furthermore, data from non-
clinical routine sources may inform outcomes beyond the standard RCT assessments of clinical 
efficacy and effectiveness. For example, cost data (such as use of healthcare resources) and socio-
economic data (such as employment and means-tested benefits data) may inform health economic 
analyses and the assessment of the broader societal impact of healthcare interventions.    
The potential benefits of using routinely recorded data in clinical research have resulted in a political 
drive to increase implementation, detailed in The Plan for Growth [9] and The NHS constitution [10], 
where research is presented as a core activity making the link explicit between the provision of NHS 
services and research. Consequently, initiatives such as the Administrative Data Research Network 
[11] have been established to provide a method of access to individual-level data, linking clinical and 
non-clinical sources of routinely recorded data.   
The objective of this paper is to review relevant sources of routinely recorded data for England, 
Scotland and Wales and discuss our experience with the feasibility of accessing individual-level data 
for a subgroup of participants enrolled into a RCT before finally proposing recommendations for 
improving the access and implementation of routinely collected data in RCTs. This is an on-going 
study and in a future publication we aim to assess the agreement of routinely recorded data compared 
to paired data collected in a RCT using standard prospective methods.   
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Methods 
The case study RCT is the Standard and New Antiepileptic Drugs (SANAD) II Trial. SANAD II is a 
pragmatic, UK multicentre, phase IV RCT funded by the National Institute for Health Research 
(NIHR) HTA programme, assessing the clinical and cost effectiveness of a number of antiepileptic 
drugs as first line treatments for newly diagnosed epilepsy. Data for clinical outcomes including 
seizure freedom and adverse events are recorded on Case Report Forms by the treating clinical team 
during outpatient appointments. Data to inform cost effectiveness analyses including healthcare 
resource use and quality of life are recorded through participant completion of questionnaires. 
SANAD II is currently recruiting and is expected to report in 2019.  
Following research ethics and governance approvals, 470 participants enrolled in SANAD II were 
invited to provide written consent to permit the request of routinely recorded data for the duration of 
their participation in SANAD II. Ninety eight (20.9%) participants provided consent and were 
included in the study. Relevant sources of routinely recorded data were identified and detailed scoping 
discussions ensued. Subsequently where accessible, routinely recorded data for participants recruited 
into SANAD II were requested through formal applications.  
The routinely recorded data sources included in this study are as follows:   
- Clinical Routine Data Sources: Secondary Care: 
o The Health and Social Care Information Centre (HSCIC) 
o The NHS Wales Informatics Service (NWIS) 
o The NHS National Services Scotland; Information Services Division (ISD) 
- Clinical Routine Data Sources: Primary Care: 
o The Clinical Practice Research Datalink (CPRD) 
o ResearchOne 
o QResearch 
o The Health Improvement Network (THIN) Database 
o North West eHealth (NWEH) 
- Non-Clinical Routine Data Sources: 
o The Office for National Statistics (ONS) 
o HM Revenue and Customs (HMRC) 
o The Department for Work and Pensions (DWP) 
o The Driver and Vehicle Licensing Authority (DVLA) 
- ‘Linked’ Routine Data Sources: 
o The Secure Anonymised Information Linkage (SAIL) Databank 
o The Administrative Data Research Network (ADRN)  
 
In a future publication, the agreement between routinely recorded data and data collected using 
standard prospective methods will be assessed for baseline variables such as gender, age and date of 
first seizure and for outcome measures relevant to SANAD II such as time to 12 month remission 
from seizures. To assess agreement between paired continuous data, Bland Altman methods will be 
employed. Acceptable clinical limits of agreement for each variable or SANAD II outcome will be 
specified a priori and compared to the 95% confidence limits of agreement. To assess agreement 
between paired, nominal categorical datasets, cross tabulations will be constructed followed by 
calculation of Cohen’s Kappa.  
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Results 
Clinical Routine Data Sources: Secondary Care 
Electronic medical records of patients’ use of secondary care services in the UK are routinely 
managed on a national basis. A number of public service organisations provide national information, 
data and IT systems for commissioners, analysts and clinicians in health and social care. Data is 
recorded to inform patient care, provide the data for remuneration for Hospital Trusts and is 
subsequently used to monitor and improve clinical services through clinical research. Table 1 
summarises the data sources where access to individual-level data is possible.    
Table 1: Example sources of Routinely Recorded Secondary Care Data 
Clinical Routine Data Sources: Primary Care 
Electronic medical records of patients’ use of primary care services in the UK are recorded routinely 
by the General Practitioner to inform patient care and remuneration, but are not currently available for 
clinical research on a national basis. A number of organisations represent collaborations between 
governmental bodies or academic institutions and providers of Primary Care IT systems. Access on a 
regional basis is possible through a number of data sources summarised in Table 2.      
Table 2: Example sources of Routinely Recorded Primary Care Data 
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Non-Clinical Routine Data Sources 
Non-clinical, individual-level data are routinely recorded by a number of UK governmental 
departments for a variety of indications. Selected organisations record data that would be informative 
to prospective clinical research in epilepsy and other diseases, summarised in Table 3.    
Table 3: Example sources of Routinely Recorded Non-Clinical Data 
‘Linked’ Routine Data Sources 
In order to provide a ‘complete’ dataset of the information required to meet research objectives, data 
from a number of organisations may need to be accessed. This is typically accomplished by linking 
data sources using identifiers such as patients’ name, date of birth, National Insurance Number or 
NHS Number. In response to the growing recognition of the potential of routinely recorded data, 
initiatives have been established to assist with the provision of linked, de-identified, aggregate data 
between data sources:    
- The Secure Anonymised Information Linkage (SAIL) Databank is an initiative developed 
by Swansea University and funded by the Welsh Government. SAIL provides a method of 
access to individual-level, routinely-recorded, de-identified electronic data for patients across 
Wales to support research [36]. Access to clinical datasets provided by NWIS is 
complemented with numerous non-clinical administrative datasets including births, deaths 
and demographic data. Following the scoping process a formal application is submitted to the 
Information Governance Review Panel before access to data is granted. SAIL data has been 
accessed to measure clinical outcomes in retrospective research [37].  
- The Administrative Data Research Network (ADRN) is a UK-wide partnership between 
universities, government departments, national statistics authorities, funders and researchers, 
funded by the Economic and Social Research Council. ADRN provides a method of access to 
a number of non-clinical administrative routine datasets including employment, 
socioeconomic, crime and education data [11] in addition to clinical datasets detailed 
previously such as those recorded by the HSCIC. Following development of a project 
proposal a formal application is reviewed by the Approvals Panel before access to data is 
granted.  
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Challenges and Feasibility of Access 
We have requested access to routinely recorded data for individuals enrolled in the SANAD II RCT, 
resident in England and Wales who have provided written consent. There were insufficient 
participants meeting the eligibility criteria resident in Scotland. Data sources were identified and 
scoping discussions informed the initial assessment of feasibility. Data sources were deemed feasible 
if individual-level data could be provided for specified individuals providing consent. Resources 
required including cost and researcher time were also factors important in the assessment of 
feasibility. Including the preparation, research ethics and governance approval and submission of the 
applications for data access, significant researcher time and a period of 18 months were required. The 
feasibility, timeline and key milestones involved for each data source are summarised in Table 4.        
Clinical Routine Data Sources 
Routinely recorded secondary care data can be requested on an individual-level, identifiable basis for 
patients in England and Wales through HSCIC and NWIS, accessed through SAIL and in our 
experience this process is feasible as part of a RCT, yet there are notable limitations. In England, the 
HSCIC has set a target time to data access of 60 working days following submission for a complex 
application, involving bespoke data linkage from multiple datasets. From the date of submission of 
the Data Access Request Service online application we have been granted access to the data within 
this timeframe. However, this positive experience following submission of the application is 
countered by limitations in the pre-application process. Acknowledging the significant update to 
online application and approval procedures that occurred during this period, there remains a 
considerable period of time required in the development of the application. The nature of the request 
for identifiable data necessitated participant consent as the valid legal basis. The HSCIC require 
ethical and governance approval to be in place prior to DARS review and to prevent future 
amendments and delays, it was rational to ensure the consent materials had been reviewed by the 
HSCIC Information Governance team, prior to submitting the documents for ethical and governance 
approval. HSCIC provide written guidance regarding the consent materials and advise documents 
should be reviewed. However, in our experience there is no formalised process for providing this 
review. Following significant correspondence the consent materials were reviewed by the Data 
Access and Information Sharing Team. However, this feedback was provided following a formal 
submission and review by the Data Access Request Service. Formalising the process for the review of 
consent materials would likely improve the time and resource efficiency for both HSCIC and the 
researcher.  
For participants in Wales, we have requested secondary care data and for a proportion of participants 
primary care data through SAIL Databank. SAIL provided a streamlined pre-application service, 
including engaging in multiple discussions and completion of a scoping document, outlining the study 
methods and costs involved. Consent materials were also promptly reviewed by a member of the 
Information Governance team.  
Common to both sources of secondary care routinely recorded data; there are stringent information 
governance requirements that must be in place prior to application. These include information security 
measures and assessments, specific inclusion regarding the ‘processing of healthcare data for the 
subjects of research’ in the institutional Data Protection Act registration and in the case of HSCIC, an 
institutional Data Sharing Framework Contract. Adequate guidance is provided by the data sources 
and if not addressed by the researcher, may cause delay. Furthermore, there is a time lag of 
approximately 3-6 months before data becomes available within each data source. This delay 
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potentially limits the utility of such sources in prospective clinical research, such as drug trials where 
prompt reporting is clinically important and a regulatory requirement.  
Routinely recorded primary care data for specific participants in England is less accessible. The 
majority of providers of primary care data such as ResearchOne and QResearch provide data on a de-
identified basis with no facility to re-identify individuals. Therefore, where specific participants need 
to be identified, as for RCTs such as SANAD II, these sources are not applicable. Following our 
correspondence, CPRD confirmed it may be possible to retrieve identifiable individual-level data, 
linked to HSCIC data in the future, but the required approvals were not in place and the timescale to 
resolution was unclear. Furthermore, such primary care sources provide data for only a proportion of 
the population and can be expensive.  
NorthWest eHealth employs an alternative methodology whereby primary care data is extracted 
directly from the GP through a third party. This process requires participant and GP consent and 
installation of the required software but is an effective data extraction method [27]. NWEH offers a 
number of primary care research tools for the wider research community but does not currently 
routinely provide a bespoke primary care data extraction service for research.      
Non-Clinical Routine Data Sources 
Aggregate economic and societal statistics, provided by Lower Layer Super Output Area (LSOA) can 
be accessed through the ONS and are in the public domain. Such data may have additional benefits to 
the analyses of health and socio-economic outcomes in RCTs. Individual-level economic data from 
sources such as DWP and HMRC would likely be informative to prospective clinical research as such 
data are often poorly or incompletely recorded using standard methods [38]. However, relevant to this 
study, there is no previous evidence of access to DWP or HMRC individual-level or aggregate data 
for clinical research.   
During scoping discussions with DWP and HMRC, we were directed to the ADRN but this network 
has not been successful in negotiating data access.   
Finally, the outcomes of selected clinical studies may be measured using DVLA data. However, the 
DVLA declined the request for access, citing insufficient internal resources to process the request and 
more stringent data protection requirements than those employed in the NHS or academic institutions, 
without providing explicit details regarding these requirements.    
Table 4: Summary of Key Application Milestones  
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Discussion 
Routinely recorded data are valid for use in retrospective clinical research [3, 4] and have the potential 
to be used in prospective research including measuring the outcomes of RCTs [7] and providing 
additional benefits such as a method to address missing RCT data. Limitations, specifically with 
respect to accuracy and access have been recognised for some time. Academic, political [9] and health 
service [10] interest in UK sources of routinely recorded data has resulted in expansion and 
improvements, notably in the access to linked datasets. However our experience with accessing 
individual-level data for specific participants providing written consent to inform the outcomes of a 
RCT, highlight persisting limitations.  
Clinical routine data sources are numerous and there is comprehensive national coverage of secondary 
care data. In our experience, accessing individual level data is feasible. However, inefficiencies in the 
application processes persist, particularly during the informal ‘pre-application’ phase. The notable 
limitation encountered was obtaining feedback on the Patient Information Sheet and Consent Form 
prior to ethical and governance review. Formalising an explicit review process for consent materials 
would improve the efficiency for both the data holders and the research team.  
Access to routinely recorded individual - level primary care data has not been feasible. Each primary 
care data source has limited geographical coverage often based on GP IT system, usually process de-
identified data and may incur significant expense. The inception of the HSCIC General Practice 
Extraction Service which records primary care data nationally for England, represents the most 
optimistic national source, however access is currently restricted to Department of Health initiatives, 
such as research involving screening procedures [39]. 
The access to non-clinical data sources for clinical research has not been possible. The ADRN has 
been established to act on behalf of the researcher in negotiating access to de-identified, linked 
routinely recorded data from a number of organisations and the study proposal was promptly directed 
to the ADRN. However, the decision whether to release data remains with the data holder. 
Ideologically, the next step would be the storage of de-identified linked data from participating 
organisations in a single repository, similar to those established for RCT data [40]. This would create 
a single point of access and remove the burden for each organisation to consider each study 
individually. This would however require significant information governance and security barriers to 
be cleared and in light of recent developments within the research climate, individual consent. 
Including patients as stakeholders in the development of such data sources is essential [41].  
Although there are examples of pragmatic RCTs being coordinated through routine data sources [8], 
there are likely to be limitations when accessing routinely recorded data to measure the outcomes of 
RCTs. Quality assurance is unclear and the level of agreement of routinely recorded data with data 
recorded through standard RCT methods remains uncertain, particularly when measuring clinical 
outcomes. The time delay before routinely recorded data becomes available may have implications for 
RCTs where prompt reporting is both clinically important and a regulatory requirement. Furthermore 
the pre-application and application process may introduce further delays. This will have implications 
for RCTs relying on routinely recorded data. The cost efficiency of accessing routinely recorded data, 
compared to standard methods is unclear. Further research is required to assess the agreement, 
additional benefits and cost efficiency of routinely recorded data compared to data collected through 
standard RCT methods; it may be in the additional benefits such as addressing missing RCT data 
where routinely recorded data is most useful.      
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Conclusions 
The failure of access to routinely recorded data for a purpose such as this study with clear secondary 
benefit to clinical research methodology seems inappropriate when the ‘public purse’ funds the 
research, the researcher and the public body holding the data. Perhaps a significant cause or 
contributor to the current limitations is the Care.Data initiative in 2014. The proposal to extract 
primary care records from all patients was opposed publicly by a number of groups and for example, 
resulted in an internal inquiry within the HSCIC. Data applications were suspended during this period 
and our current experience may be explained by the concurrent revision of the HSCIC application and 
approval procedures. However, in the medium term, of more concern is the harm in public perception 
that resulted. Currently, more than 1.2 million individuals in the UK have submitted a ‘Type 2 
objection’, meaning that their data will not be shared for purposes other than direct care [42]. 
Although the application procedures may improve and in time we may be able to access data more 
efficiently, the loss of 2.2% of the population will have implications for the routinely recorded data 
that will then be made available for research. Involving patients as important stakeholders and re-
gaining their trust will be an essential factor in realising the individual and population healthcare 
benefits of routinely recorded data [43].    
Recommendations 
We propose recommendations to improve access and implementation of routinely recorded data 
during a RCT, summarised in Table 5.  
Table 5: Recommendations to Improve Access to Routinely Recorded Data for Research 
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